[154 Pages Report] Viral Inactivation Market report categorizes the global market by Application (Stem Cell, Blood, Tissue, Cell & Gene Therapy), Product (Reagents, Systems, Kits, Services), Method (Pasteurization, Solvent Detergent), End User (Pharmaceutical and Biotechnology, CROs) & Geography
- Advertising -
Browse 72 market data tables with 70 figures spread through 154 pages and in-depth TOC on "Viral Inactivation Market"
The global viral inactivation market was valued at USD 320.5 Million in 2016. This market is expected to grow at a CAGR of 12.3% to reach USD 573.0 Million in 2021.
The global viral inactivation market is segmented on the basis of method, product, application, end user, and geography.
- Advertising -
By method, the market is divided into solvent detergent method, pasteurization, and other methods. Other viral inactivation method includes low pH, microwave heating, irradiation, and high-energy light.
Of these, the solvent detergent method segment accounted for the largest share of the global viral inactivation market in 2015.
The application segments included in this report are blood & blood products, cellular & gene therapy products, stem cell products, tissue & tissue products, and vaccines and therapeutics. Of these the vaccines and therapeutics application hold the highest share.
Download PDF Brochure: www.marketsandmarkets.com/pdfdownload.asp?id=121427017
By end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and other end users. Other end user segment primarily includes cell banks, small cell culture laboratories and consultants, microbiology laboratories, immunology laboratories, molecular laboratories, animal facilities, toxicology laboratories, and media/sera manufacturers.
The product segments included in the report are kits and reagents, services, and viral inactivation systems and accessories.
Rapidly increasing pharmaceutical and biotechnology industries and increasing number of new biologics products launched will be the two most important growth drivers for this market in the forecasted period (2016-2021). For instance, the number of new biologics products launched annually witnessed a strong upward trend between 2003 and 2013.
The number of new products launched in 2013 was 56 as compared to 29 in 2003. The biologics pipeline has increased by 155%, from 355 treatments in 2001 to 907 in 2012.
A strong pharmaceutical product pipeline will aid the growth of the pharmaceutical and biotechnology industry, which is an important end user of viral inactivation products.
Access Report: www.marketsandmarkets.com/speaktoa….asp?id=121427017
The geographic segments included in this report are Asia, Europe, North America, and the Rest of the World (RoW). The North America segment is further divided into Canada and the U.S.
Asia segment is further divided into China, Japan, India, and Rest of Asia.
Major players in the viral inactivation market include Clean Cells (France), Charles River Laboratories International, Inc. (U.S.), Danaher Corporation (U.S.), Merck KGaA (Germany), Parker Hannifin (U.S.), Rad Source Technologies (U.S.), Sartorius AG (Germany), SGS S.A. (Switzerland), Texcell, Inc. (France), Viral Inactivated Plasma Systems SA (Switzerland), and WuXi PharmaTech (Cayman) Inc. (China).
Category: Market Research Publishers and RetailersCompany profile: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth ...
For more information: